OptiPin
Cartalax: uses, dosing & the facts
A short synthetic peptide bioregulator (Ala-Glu-Asp-Pro) developed alongside Epitalon and Pinealon, aimed at cartilage and connective tissue. Published human data is limited. This is an evidence-graded reference – what it is, what it's used for, typical reported dosing, half-life, side effects, and how to track it. It is educational, not medical advice or a recommendation to use a research compound.
- • Cartalax – Longevity. A short synthetic peptide bioregulator (Ala-Glu-Asp-Pro) developed alongside Epitalon and Pinealon, aimed at cartilage and connective tissue.
- • Commonly used for cartilage and joint support, connective tissue recovery, age-related joint stiffness.
- • Half-life: Short half-life.
- • Status: Research use only · not FDA-approved – an educational reference, not a dose protocol or sourcing advice.
What Cartalax is
A short synthetic peptide bioregulator (Ala-Glu-Asp-Pro) developed alongside Epitalon and Pinealon, aimed at cartilage and connective tissue. Published human data is limited.
What Cartalax is used for
- • Cartilage and joint support
- • Connective tissue recovery
- • Age-related joint stiffness
- • Musculoskeletal maintenance protocols
- • Stacked with other peptide bioregulators
These are reported/community uses, not proven clinical outcomes. Most research peptides have limited human trial data behind such claims.
Typical reported dosing
| Injectable | 5–20mg injected subcutaneously or intramuscularly daily for a short course, commonly 10 days |
Presented as commonly-reported patterns for information only – not a dose recommendation. Cartalax dosing is a decision for a qualified clinician.
Reconstitution
Reconstitute with bacteriostatic water. Sold either lyophilised or as a pre-formulated solution. The arithmetic is the same for any peptide: concentration = vial mg ÷ water mL, and on a U-100 syringe 100 units = 1 mL. Compute your own vial with the reconstitution calculator.
Half-life & cycling
Half-life: Short half-life. Half-life drives dosing frequency and how quickly the compound clears – see it plotted on the Cartalax half-life calculator.
Cycling
Typical course: 10–20 consecutive days, then a break of several months. Usually repeated 1–2 times per year rather than run continuously.
Side effects & warnings
- an injection site that turns red, hot or hard, spreads, weeps, or comes with a fever – same-day medical care – research-grade material carries no sterility guarantee, so abscess and cellulitis are the documented consequence
- swelling of the lips, tongue or throat, trouble breathing, or widespread hives after a dose – emergency care
- • Generally well-tolerated
- • Minimal reported side effects
- • Mild injection site reactions possible
Research use only. Not an approved medicine in most countries, and published human evidence is sparse, so treat reported benefits as unproven. Used in short courses rather than continuously. Not a substitute for proper assessment of a painful or degenerating joint.
Tracking Cartalax in OptiPin
If you're tracking a Cartalax protocol, OptiPin logs each dose with reminders and site rotation, charts the outcome you care about over your dose timeline, keeps per-vial inventory with runout warnings, and (where relevant) does the reconstitution math – all on-device, no account.
Log doses, outcomes & vials in OptiPin
Reminders, outcome-over-dose charts, vial runout warnings, and built-in reconstitution math – all on-device.
Download on the App StoreFAQ
What is Cartalax?
A short synthetic peptide bioregulator (Ala-Glu-Asp-Pro) developed alongside Epitalon and Pinealon, aimed at cartilage and connective tissue. Published human data is limited.
What is Cartalax used for?
Commonly discussed uses include: cartilage and joint support, connective tissue recovery, age-related joint stiffness, musculoskeletal maintenance protocols, stacked with other peptide bioregulators. These are reported uses, not proven outcomes or a recommendation.
How is Cartalax dosed?
Commonly reported dosing: Injectable – 5–20mg injected subcutaneously or intramuscularly daily for a short course, commonly 10 days. This reflects patterns discussed in the community and is presented for information only, not as a dose recommendation – Cartalax is not an approved medicine and dosing should involve a qualified clinician.
How do you reconstitute Cartalax?
Reconstitute with bacteriostatic water. Sold either lyophilised or as a pre-formulated solution. On a U-100 syringe, 100 units = 1 mL. Concentrations vary by vial, so compute from your own vial with a reconstitution calculator.
What is Cartalax's half-life?
Short half-life. Half-life shapes how often it is dosed and how quickly it clears.
What are Cartalax's side effects?
Reported effects include: generally well-tolerated, minimal reported side effects, mild injection site reactions possible. Because it is a research compound, its safety profile is not fully characterized; discuss risks with a clinician.
Evidence & further reading
- Search the peer-reviewed literature for Cartalax on PubMed (entry point to the primary evidence base, not a specific citation).
- Cartalax on ClinicalTrials.gov – registered human trials, if any.
- US FDA / 503A compounding status of research peptides (2026).
- OptiPin peptides guide – categories, evidence grading, and how to run a protocol honestly.
Related
Cortagen · Epitalon · GLOW · Humanin · nad-plus · Reconstitution calculator · All peptides